Alphamab Oncology has developed multiple technology platforms for biologics through a deep understanding of protein structure and function, combined with artificial intelligence/machine learning (AI/ML). These technology platforms include single-domain antibodies, bispecific antibodies, glycan-specific conjugation, dual-payload conjugation, linker-payload, and high-concentration subcutaneous formulations platforms.
We focus on multidimensional antibody engineering and modification technology platforms, continuously developing a product portfolio with differentiated innovation and global competitiveness to provide more effective and safer treatment options for cancer patients.
